TuHURA Biosciences (NASDAQ:HURA) Issues Earnings Results

TuHURA Biosciences (NASDAQ:HURA) posted its quarterly earnings results on Friday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Price Performance

NASDAQ:HURA opened at $2.05 on Friday. The business’s 50-day moving average is $2.45 and its two-hundred day moving average is $2.73. The firm has a market capitalization of $105.08 million and a PE ratio of -1.18. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.20.

Institutional Trading of TuHURA Biosciences

Large investors have recently bought and sold shares of the company. Bank of America Corp DE acquired a new position in shares of TuHURA Biosciences during the fourth quarter worth $59,000. Jane Street Group LLC acquired a new position in TuHURA Biosciences in the 1st quarter worth $69,000. Geode Capital Management LLC lifted its holdings in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in TuHURA Biosciences in the 2nd quarter valued at about $27,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of TuHURA Biosciences during the second quarter valued at about $97,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

Wall Street Analyst Weigh In

HURA has been the topic of several research analyst reports. Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Finally, Maxim Group lowered their price objective on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $10.33.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.